Related references
Note: Only part of the references are listed.Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
Stuart E. Lacy et al.
BLOOD (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Rho-Family Small GTPases: From Highly Polarized Sensory Neurons to Cancer Cells
Takehiko Ueyama
CELLS (2019)
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Weiping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma
Afua A. Mensah et al.
HAEMATOLOGICA (2018)
STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas
Yi-Ru Pan et al.
NATURE COMMUNICATIONS (2018)
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors
Enrico Derenzini et al.
CELL REPORTS (2018)
Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1
Hirotada Tajiri et al.
CELL REPORTS (2017)
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
Elena Bernasconi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Anton Henssen et al.
CLINICAL CANCER RESEARCH (2016)
Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue
Elias E. Stratikopoulos et al.
CLINICAL CANCER RESEARCH (2016)
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
Vivek Asati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression
Esther Castellano et al.
NATURE COMMUNICATIONS (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition
Steven Tinsley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
Elias E. Stratikopoulos et al.
CANCER CELL (2015)
IQGAPs choreograph cellular signaling from the membrane to the nucleus
Jessica M. Smith et al.
TRENDS IN CELL BIOLOGY (2015)
Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas
Kui Wu et al.
NATURE COMMUNICATIONS (2015)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W. Scott et al.
BLOOD (2014)
Diffuse large B-cell lymphoma-treatment approaches in the molecular era
Mark Roschewski et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
Michele Ceribelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Therapeutic Strategies to Inhibit MYC
Michael R. McKeown et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Super-Enhancers in the Control of Cell Identity and Disease
Denes Hnisz et al.
CELL (2013)
Targeting Epigenetic Readers in Cancer
Mark A. Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
Peter Friedl et al.
CELL (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis
Chia-Hsin Chan et al.
NATURE CELL BIOLOGY (2010)
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Georg Lenz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
IQGAP3, a novel effector of Rac1 and Cdc42, regulates neurite outgrowth
Shujie Wang et al.
JOURNAL OF CELL SCIENCE (2007)
Tumour-cell invasion and migration: Diversity and escape mechanisms
P Friedl et al.
NATURE REVIEWS CANCER (2003)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
